CMMB Chemomab Therapeutics
Chemomab Therapeutics earnings company data as of 6:17 PM ET 10/23
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 29 Oct | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 20 Aug | EPS | 0.00 | 0.00 | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by CMMB's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $20K bought by 1 insider
- $6,516 sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Neil Harris Cohen DirectorSale$6,516 2,304 shares at $2.83 6.5% of stakeTraded Aug 27–28 Filed Sep 1
-
George Adi Mor CEOBuy$20K 9,804 shares at $2.07 +7.6% to stakeTraded May 29 Filed Jun 1
Also filed in the last 12 months, not counted as buying or selling: 2 other transactions.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| SCHEDULE 13D/A | — | Filing Doc | |
| 6-K | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13D | — | Filing Doc | |
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| 20-F | Filing Doc | ||
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 424B5 | Filing Doc | ||
| 6-K | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.